U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H39NO9.ClH
Molecular Weight 582.082
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMACETAXINE MEPESUCCINATE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12[C@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]13CCCN3CCC4=CC5=C(OCO5)C=C24

InChI

InChIKey=RRNSZQVHVKGKOS-CALFFDBBSA-N
InChI=1S/C29H39NO9.ClH/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28;/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3;1H/t24-,25-,28+,29-;/m1./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C29H39NO9
Molecular Weight 545.6213
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23790799

Omacetaxine mepesuccinate (trade name Synribo) formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). It is a natural ester of the alkaloid cephalotaxine from Cephalotaxus harringtonia, now manufactured by hemi-synthesis. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr Abl oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models of wild-type and T315I mutated Bcr-Abl CML.

CNS Activity

CNS Active
3913
Curator's Comment: Homoharringtonine (omacetaxine mepesuccinate) can penetrate into brain tumors. Generally tritiated homoharringtonine ([3H]HHT, 150 microCi, 430 micrograms) was administered intravenously to seven patients at varying times before surgical resection of malignant brain tumor. Plasma, urine, cerebrospinal fluid (CSF), and tumor specimens were obtained during surgery, and the concentrations of HHT, its major metabolite, and [3H]HHT equivalent were determined chromatographically and radiochemically. A major metabolite of HHT was detectable in the tumor specimens of all the patients.

Originator

U.S. Department of Agriculture
3
Curator's Comment: Homoharringtonine (omacetaxine mepesuccinate ) and related compound esters of cephalotaxine were described first in 1970. Omacetaxine mepesuccinate has been marketed by IVAX International GmbH (Teva) under the trade name SYNRIBO approved by FDA in 2012.

Approval Year

2012
595
Targets

Targets

Primary TargetPharmacologyConditionPotency
60S ribosomal protein L3
3
Target ID: P39023
Gene ID: 6122.0
Gene Symbol: RPL3
Target Organism: Homo sapiens (Human)
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
SYNRIBO

Approved Use

Indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate.There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO

Launch Date

2012
Primary
Approved
8429
SYNRIBO

Approved Use

Indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate.There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
25.1 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/23053254
1.25 mg/m² single, subcutaneous
dose: 1.25 mg/m²
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
[NO STEREO] OMACETAXINE MEPESUCCINATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
136.2 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/23053254
1.25 mg/m² single, subcutaneous
dose: 1.25 mg/m²
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
[NO STEREO] OMACETAXINE MEPESUCCINATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.96 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/23053254
1.25 mg/m² single, subcutaneous
dose: 1.25 mg/m²
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
[NO STEREO] OMACETAXINE MEPESUCCINATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg/m2 1 times / day multiple, subcutaneous
MTD
Dose: 5 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
DLT: Haematemesis, Pulmonary aspergillosis...
Other AEs: Anasarca...
Dose limiting toxicities:
Haematemesis (grade 3, 1 patient)
Pulmonary aspergillosis (grade 4, 1 patient)
Skin rash (grade 3, 1 patient)
Scalp pain (grade 3, 1 patient)
Other AEs:
Anasarca (grade 3, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
3 mg/m2 1 times / day multiple, subcutaneous
Dose: 3 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 3 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
DLT: Hyperglycaemia, Diabetic hyperosmolar coma...
Dose limiting toxicities:
Hyperglycaemia (grade 3, 1 patient)
Diabetic hyperosmolar coma
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Disc. AE: Thrombocytopenia, Alanine aminotransferase increased...
Other AEs: Thrombocytopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (2%)
Alanine aminotransferase increased (2%)
Other AEs:
Thrombocytopenia (all grades, 74%)
Thrombocytopenia (grade 3-4, 67%)
Anemia (all grades, 61%)
Anemia (grade 3-4, 36%)
Neutropenia (all grades, 50%)
Neutropenia (grade 3-4, 45%)
Lymphopenia (all grades, 17%)
Lymphopenia (grade 3-4, 16%)
Bone marrow failure (all grades, 10%)
Bone marrow failure (grade 3-4, 10%)
Febrile neutropenia (all grades, 10%)
Febrile neutropenia (grade 3-4, 10%)
Diarrhea (all grades, 42%)
Diarrhea (grade 3-4, 1%)
Nausea (all grades, 32%)
Nausea (grade 3-4, 1%)
Constipation (grade 1-2, 15%)
Abdominal pain upper (grade 1-2, 14%)
Vomiting (grade 1-2, 12%)
Fatigue (all grades, 26%)
Fatigue (grade 3-4, 5%)
Pyrexia (all grades, 24%)
Pyrexia (grade 3-4, 1%)
Asthenia (all grades, 23%)
Asthenia (grade 3-4, 1%)
Edema peripheral (grade 1-2, 13%)
Infusion site reactions (grade 1-2, 34%)
Arthralgia (all grades, 19%)
Arthralgia (grade 3-4, 1%)
Pain in extremity (all grades, 13%)
Pain in extremity (grade 3-4, 1%)
Back pain (all grades, 11%)
Back pain (grade 3-4, 2%)
Headache (all grades, 19%)
Headache (grade 3-4, 1%)
Insomnia (grade 1-2, 10%)
Cough (all grades, 16%)
Cough (grade 3-4, 1%)
Epistaxis (all grades, 15%)
Epistaxis (grade 3-4, 1%)
Alopecia (grade 1-2, 15%)
Rash (grade 1-2, 10%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 158
Health Status: unhealthy
Condition: chronic phase, Accelerated Phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 158
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Disc. AE: Bone marrow failure, Sepsis...
AEs leading to
discontinuation/dose reduction:
Bone marrow failure (1%)
Sepsis (1%)
Multiorgan failure (1%)
Gout (1%)
Renal failure (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Other AEs: Anemia, Anemia...
Other AEs:
Anemia (all grades, 51%)
Anemia (grade 3-4, 36%)
Febrile neutropenia (all grades, 20%)
Febrile neutropenia (grade 3-4, 16%)
Neutropenia (all grades, 20%)
Neutropenia (grade 3-4, 18%)
Thrombocytopenia (all grades, 56%)
Thrombocytopenia (grade 3-4, 49%)
Diarrhea (all grades, 35%)
Diarrhea (grade 3-4, 7%)
Nausea (all grades, 27%)
Nausea (grade 3-4, 4%)
Vomiting (all grades, 15%)
Vomiting (grade 3-4, 2%)
Abdominal pain (grade 1-2, 13%)
Fatigue (all grades, 31%)
Fatigue (grade 3-4, 9%)
Pyrexia (all grades, 29%)
Pyrexia (grade 3-4, 2%)
Asthenia (all grades, 24%)
Asthenia (grade 3-4, 2%)
Chills (grade 1-2, 13%)
Infusion site reactions (grade 1-2, 22%)
Anorexia (all grades, 13%)
Anorexia (grade 3-4, 2%)
Pain in extremity (all grades, 11%)
Pain in extremity (grade 3-4, 2%)
Headache (grade 1-2, 13%)
Cough (grade 1-2, 15%)
Dyspnea (all grades, 11%)
Dyspnea (grade 3-4, 2%)
Epistaxis (all grades, 11%)
Epistaxis (grade 3-4, 2%)
Bacterial infection (all grades, 56%)
Bacterial infection (grade 3-4, 20%)
Infection viral (all grades, 56%)
Infection viral (grade 3-4, 20%)
Fungal infection (all grades, 56%)
Fungal infection (grade 3-4, 20%)
Infection NOS (all grades, 56%)
Infection NOS (grade 3-4, 20%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Disc. AE: Pancytopenia...
AEs leading to
discontinuation/dose reduction:
Pancytopenia (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase CML
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Disc. AE: Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Alanine aminotransferase increased (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase CML
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Disc. AE: Tachyarrhythmia, Diplopia...
AEs leading to
discontinuation/dose reduction:
Tachyarrhythmia (1%)
Diplopia (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
8 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6478448
unhealthy
Health Status: unhealthy
Condition: refractory malignancies
Sources:
https://pubmed.ncbi.nlm.nih.gov/6478448
DLT: Hypotension...
Dose limiting toxicities:
Hypotension
Sources:
https://pubmed.ncbi.nlm.nih.gov/6478448
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy
n = 1
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Disc. AE: Gastrointestinal disorders, Gingival hemorrhage...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders (1 patient)
Gingival hemorrhage (1 patient)
Alopecia (1 patient)
Thrombocytopenia (grade 4, 1 patient)
Neutropenia (grade 4, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
unhealthy
n = 1
Health Status: unhealthy
Condition: CML
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
Disc. AE: Gingival hemorrhage, Gastrointestinal disorders...
AEs leading to
discontinuation/dose reduction:
Gingival hemorrhage (1 patient)
Gastrointestinal disorders (1 patient)
Alopecia (1 patient)
Thrombocytopenia (grade 4, 1 patient)
Neutropenia (grade 4, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
AEs

AEs

AESignificanceDosePopulation
Anasarca grade 3, 1 patient
5 mg/m2 1 times / day multiple, subcutaneous
MTD
Dose: 5 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Haematemesis grade 3, 1 patient
DLT
5 mg/m2 1 times / day multiple, subcutaneous
MTD
Dose: 5 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Scalp pain grade 3, 1 patient
DLT
5 mg/m2 1 times / day multiple, subcutaneous
MTD
Dose: 5 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Skin rash grade 3, 1 patient
DLT
5 mg/m2 1 times / day multiple, subcutaneous
MTD
Dose: 5 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Pulmonary aspergillosis grade 4, 1 patient
DLT
5 mg/m2 1 times / day multiple, subcutaneous
MTD
Dose: 5 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 5 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Diabetic hyperosmolar coma DLT
3 mg/m2 1 times / day multiple, subcutaneous
Dose: 3 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 3 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Hyperglycaemia grade 3, 1 patient
DLT
3 mg/m2 1 times / day multiple, subcutaneous
Dose: 3 mg/m2, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 3 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
unhealthy, 57 years (range: 20–79 years)
n = 12
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Age Group: 57 years (range: 20–79 years)
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/16847470
Alanine aminotransferase increased 2%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Thrombocytopenia 2%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Bone marrow failure all grades, 10%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Febrile neutropenia all grades, 10%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Back pain all grades, 11%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pain in extremity all grades, 13%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Epistaxis all grades, 15%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Cough all grades, 16%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Lymphopenia all grades, 17%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Arthralgia all grades, 19%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Headache all grades, 19%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Asthenia all grades, 23%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pyrexia all grades, 24%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Fatigue all grades, 26%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Nausea all grades, 32%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Diarrhea all grades, 42%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Neutropenia all grades, 50%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Anemia all grades, 61%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Thrombocytopenia all grades, 74%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Insomnia grade 1-2, 10%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Rash grade 1-2, 10%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Vomiting grade 1-2, 12%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Edema peripheral grade 1-2, 13%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Abdominal pain upper grade 1-2, 14%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Alopecia grade 1-2, 15%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Constipation grade 1-2, 15%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Infusion site reactions grade 1-2, 34%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Arthralgia grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Asthenia grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Cough grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Diarrhea grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Epistaxis grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Headache grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Nausea grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pain in extremity grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pyrexia grade 3-4, 1%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Bone marrow failure grade 3-4, 10%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Febrile neutropenia grade 3-4, 10%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Lymphopenia grade 3-4, 16%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Back pain grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Anemia grade 3-4, 36%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Neutropenia grade 3-4, 45%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Fatigue grade 3-4, 5%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Thrombocytopenia grade 3-4, 67%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Bone marrow failure 1%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 158
Health Status: unhealthy
Condition: chronic phase, Accelerated Phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 158
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Gout 1%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 158
Health Status: unhealthy
Condition: chronic phase, Accelerated Phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 158
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Multiorgan failure 1%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 158
Health Status: unhealthy
Condition: chronic phase, Accelerated Phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 158
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Renal failure 1%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 158
Health Status: unhealthy
Condition: chronic phase, Accelerated Phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 158
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Sepsis 1%
Disc. AE
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 158
Health Status: unhealthy
Condition: chronic phase, Accelerated Phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 158
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Dyspnea all grades, 11%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Epistaxis all grades, 11%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pain in extremity all grades, 11%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Anorexia all grades, 13%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Vomiting all grades, 15%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Febrile neutropenia all grades, 20%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Neutropenia all grades, 20%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Asthenia all grades, 24%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Nausea all grades, 27%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pyrexia all grades, 29%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Fatigue all grades, 31%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Diarrhea all grades, 35%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Anemia all grades, 51%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Bacterial infection all grades, 56%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Fungal infection all grades, 56%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Infection NOS all grades, 56%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Infection viral all grades, 56%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Thrombocytopenia all grades, 56%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Abdominal pain grade 1-2, 13%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Chills grade 1-2, 13%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Headache grade 1-2, 13%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Cough grade 1-2, 15%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Infusion site reactions grade 1-2, 22%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Febrile neutropenia grade 3-4, 16%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Neutropenia grade 3-4, 18%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Anorexia grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Asthenia grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Dyspnea grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Epistaxis grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pain in extremity grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pyrexia grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Vomiting grade 3-4, 2%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Bacterial infection grade 3-4, 20%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Fungal infection grade 3-4, 20%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Infection NOS grade 3-4, 20%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Infection viral grade 3-4, 20%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Anemia grade 3-4, 36%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Nausea grade 3-4, 4%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Thrombocytopenia grade 3-4, 49%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Diarrhea grade 3-4, 7%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Fatigue grade 3-4, 9%
1.25 mg/m2 2 times / day multiple, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 55
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia – Accelerated Phase
Age Group: 59 years
Population Size: 55
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Pancytopenia 2%
Disc. AE
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase chronic myeloid leukemia
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Alanine aminotransferase increased 2%
Disc. AE
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase CML
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Diplopia 1%
Disc. AE
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase CML
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Tachyarrhythmia 1%
Disc. AE
1.25 mg/m2 2 times / day steady, subcutaneous
Recommended
Dose: 1.25 mg/m2, 2 times / day
Route: subcutaneous
Route: steady
Dose: 1.25 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
unhealthy, 59 years
n = 108
Health Status: unhealthy
Condition: chronic phase CML
Age Group: 59 years
Sex: M+F
Population Size: 108
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 57
Hypotension DLT
8 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6478448
unhealthy
Health Status: unhealthy
Condition: refractory malignancies
Sources:
https://pubmed.ncbi.nlm.nih.gov/6478448
Alopecia 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy
n = 1
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Gastrointestinal disorders 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy
n = 1
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Gingival hemorrhage 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy
n = 1
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Neutropenia grade 4, 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy
n = 1
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Thrombocytopenia grade 4, 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
unhealthy
n = 1
Health Status: unhealthy
Condition: Chronic Myeloid Leukemia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
Alopecia 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
unhealthy
n = 1
Health Status: unhealthy
Condition: CML
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
Gastrointestinal disorders 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
unhealthy
n = 1
Health Status: unhealthy
Condition: CML
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
Gingival hemorrhage 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
unhealthy
n = 1
Health Status: unhealthy
Condition: CML
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
Neutropenia grade 4, 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
unhealthy
n = 1
Health Status: unhealthy
Condition: CML
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
Thrombocytopenia grade 4, 1 patient
Disc. AE
2.5 mg/m2 2 times / day multiple, subcutaneous
Overdose
Dose: 2.5 mg/m2, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 2.5 mg/m2, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
unhealthy
n = 1
Health Status: unhealthy
Condition: CML
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
Page: p. 67
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A
72

CYP2C19
1478

P-gp
1461
CYP
270

P-gp
1537
CYP1A
56
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1650
 no
CYP3A4
1925
 strong [Inhibition 10 uM]
CYP1A
121
 weak [Inhibition 10 uM]
CYP2C19
1553
 weak [Inhibition 10 uM]
DMHHT
3
CYP2D6
1891
 weak [Inhibition 10 uM]
CYP1A
121
 weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
270
 no
P-gp
1537
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA00BBK4
https://www.aablocks.com/goods/Goods/detail?id=AA00BBK4
AHH Chemical co.,ltd
NP-0431
http://www.ahhchemical.com/product/NP-0431.html
Aaron Chemicals
AR00BCBW
http://www.aaronchem.com/24316-19-6
AbMole Bioscience
M3942
http://www.abmole.com/products/cephalotaxine.html
Achemtek
0104-028087
http://www.achemtek.com/24316-19-6
Acorn PharmaTech
ACN-035228
http://www.acornpharmatech.com/
Ambeed
A863555
https://www.ambeed.com/products/24316-19-6.html
Angene
AGN-PC-0R05OB
http://www.angenechemical.com/productshow/AGN-PC-0R05OB.html
Aurum Pharmatech LLC
S-7655
http://www.Aurumpharmatech.com/Product/ProductDetails/S_7655
AvaChem Scientific
3156
http://www.avachem.com/productSearch.asp?3156
BLD Pharm
BD16925
http://www.bldpharm.com/products/24316-19-6.html
CSNpharm
CSN12450
https://www.csnpharm.com/products/cephalotaxine.html
Chem Scene
CS-3006
http://www.chemscene.com/24316-19-6.html
ChemFaces
CFN90919
http://www.chemfaces.com/natural/Cephalotaxine-CFN90919.html
Chemspace
CSSB00000036076
https://chem-space.com/CSSB00000036076
DC Chemicals
DC9649
http://www.dcchemicals.com/product_show-Cephalotaxlen.html
Hairui
HR120093
http://www.hairuichem.com/en/product/24316-19-6.html
Lab Network
LN00176704
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00176704
Matrix Scientific
76038
https://www.matrixscientific.com/076038.html
MedChem Express
HY-N0838
https://www.medchemexpress.com/cephalotaxlen.html
MuseChem
I002813
https://www.musechem.com/product/I002813.html
Oakwood
79392
http://www.oakwoodchemical.com/p-73475-079392.aspx
Smolecule
S523194
http://www.smolecule.com/products/s523194
Smolecule
S749414
https://www.smolecule.com/products/s749414
THE BioTek
bt-263600
https://www.thebiotek.com/product/inhibitors/bt-263600
abcr GmbH
AB479786
http://www.abcr.com/shop/en/AB479786
eNovation Chemicals
D574859
http://www.enovationchem.com/productDetails.asp?productID=D574859
eNovation Chemicals
D628756
https://www.enovationchem.com/ProductDetails.asp?ProductID=D628756
eNovation Chemicals
D679660
https://www.enovationchem.com/ProductDetails.asp?ProductID=D679660
PubMed

PubMed

TitleDatePubMed
Inhibition of protein synthesis in intact HeLa cells.
1975 Oct
Inhibition of translation in eukaryotic systems by harringtonine.
1977 Jan
Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.
2001 Apr
Formal intramolecular [5 + 2] photocycloaddition reactions of maleimides: a novel approach to the CDE ring skeleton of (-)-cephalotaxine.
2001 Sep 20
A formal total synthesis of (+/-)-cephalotaxine using sequential N-acyliminium ion reactions.
2002 Mar 21
Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells.
2002 Mar-Apr
Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
2003 Jan
Altering chemosensitivity by modulating translation elongation.
2009
[Expression and function of Ahi-1 gene in Jurkat cells].
2009 Apr
Patents

Patents

EP2177223B9
3
US2011071097
3
US2014206669
3
US2014303147
3
US4203996
3
US6734178
3
US7285546
3
WO9948894
3

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:52:45 GMT 2023
Edited
by admin
on Fri Dec 15 15:52:45 GMT 2023
Record UNII
563OX5661H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMACETAXINE MEPESUCCINATE HYDROCHLORIDE
Common Name English
CEPHALOTAXINE, 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER), HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
CAS
457895-79-3
Created by admin on Fri Dec 15 15:52:45 GMT 2023 , Edited by admin on Fri Dec 15 15:52:45 GMT 2023
PRIMARY
PUBCHEM
9851264
Created by admin on Fri Dec 15 15:52:45 GMT 2023 , Edited by admin on Fri Dec 15 15:52:45 GMT 2023
PRIMARY
DRUG BANK
DBSALT001930
Created by admin on Fri Dec 15 15:52:45 GMT 2023 , Edited by admin on Fri Dec 15 15:52:45 GMT 2023
PRIMARY
FDA UNII
563OX5661H
Created by admin on Fri Dec 15 15:52:45 GMT 2023 , Edited by admin on Fri Dec 15 15:52:45 GMT 2023
PRIMARY
Related Record Type Details
Structure of OMACETAXINE MEPESUCCINATE
PARENT -> SALT/SOLVATE
Structure of OMACETAXINE MEPESUCCINATE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of OMACETAXINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966